Home › Compare › INCPF vs RYLD

INCPF vs RYLD: Dividend Comparison 2026

INCPF yields 129.03% · RYLD yields 12.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INCPF wins by $11.91M in total portfolio value
10 years
INCPF
INCPF
● Live price
129.03%
Share price
$1.55
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11.95M
Annual income
$4,733,958.72
Full INCPF calculator →
RYLD
RYLD
● Live price
12.14%
Share price
$14.95
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$2,587.35
Full RYLD calculator →

Portfolio growth — INCPF vs RYLD

📍 INCPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINCPFRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INCPF + RYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
INCPF pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INCPF
Annual income on $10K today (after 15% tax)
$10,967.74/yr
After 10yr DRIP, annual income (after tax)
$4,023,864.91/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,031.60/yr
After 10yr DRIP, annual income (after tax)
$2,199.25/yr
At 15% tax rate, INCPF beats the other by $4,021,665.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INCPF + RYLD for your $10,000?

INCPF: 50%RYLD: 50%
100% RYLD50/50100% INCPF
Portfolio after 10yr
$6.00M
Annual income
$2,368,273.03/yr
Blended yield
39.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on INCPF right now

INCPF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
3.9
Piotroski
5/9
RYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INCPF buys
0
RYLD buys
0
No recent congressional trades found for INCPF or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINCPFRYLD
Forward yield129.03% ✓12.14%
Annual dividend / share$2.00 ✓$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$11.95M$44.5K ✓
Annual income after 10y$4,733,958.72 ✓$2,587.35
Total dividends collected$10.93M$18.8K ✓
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: INCPF vs RYLD ($10,000, DRIP)

YearINCPF PortfolioINCPF Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$23,603$12,903.23$11,914$1,213.65+$11.7K → INCPF
2$53,719$28,463.34$14,099$1,351.30+$39.6K → INCPF
3$118,021$60,542.03$16,580$1,494.55+$101.4K → INCPF
4$250,593$124,310.20$19,384$1,642.61+$231.2K → INCPF
5$514,813$246,678.79$22,535$1,794.70+$492.3K → INCPF
6$1,024,469$473,618.88$26,063$1,950.00+$998.4K → INCPF
7$1,977,016$880,834.70$29,995$2,107.69+$1.95M → INCPF
8$3,704,035$1,588,627.70$34,361$2,266.99+$3.67M → INCPF
9$6,744,972$2,781,654.52$39,194$2,427.12+$6.71M → INCPF
10$11,951,079$4,733,958.72$44,525$2,587.35+$11.91M → INCPF

INCPF vs RYLD: Complete Analysis 2026

INCPF — Stock

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.

Full INCPF Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this INCPF vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INCPF vs SCHDINCPF vs JEPIINCPF vs OINCPF vs KOINCPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.